Literature DB >> 723793

Trials of live influenza A recombinants in man during natural antigenic change in 1971-1976.

A S Beare, A P Kendal, G C Schild.   

Abstract

A long-term study is described of human trials with live recombinants derived from A/PR/8/34 (H0 N1) and successive virulent H3 N2 viruses. A/PR/8/34 was noninfectious for man and the H3 N2 strains all induced similar influenza-like illness. In each recombinant experiment, some of the progeny were adequately attenuated and potentially immunogenic. In addition, there appeared to be evidence of probable cross-protection against viruses with related but non-identical haemagglutinins. However, the degree of cross-protection depended upon the time interval between the appearance of the epidemic and vaccine viruses. Recombinants of A/PR/8/34 and a human Hsw1 strain of low virulence did not function satisfactorily, and it seemed that the suitability of A/PR/8/34 as a 'master' parent depended upon the presence of standard genetic properties in the wild parents. The replacement of A/PR/8/34 with the partially virulent virus, X-31 (H3 N2), produced a live vaccine which was infectious but poorly antigenic. A universal master strain for live influenza vaccine recombinants is probably not yet a practical possibility.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 723793     DOI: 10.1007/bf02121138

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  11 in total

1.  Clinical trials with Alice strain, live, attenuated, serum inhibitor-resistant intranasal influenza A vaccine.

Authors:  M J Spencer; J D Cherry; K R Powell; C V Sumaya; A J Garakian
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

Review 2.  Live viruses for immunization against influenza.

Authors:  A S Beare
Journal:  Prog Med Virol       Date:  1975

3.  An attenuated influenza virus vaccine: protection against homologous and heterologous strains of virus.

Authors:  J D Lee; R A Khakoo; C K Street; R H Waldman
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

4.  Segregation of antigenic and biological characteristics during influenza virus recombination.

Authors:  D McCahon; G C Schild
Journal:  J Gen Virol       Date:  1972-04       Impact factor: 3.891

5.  Future influenza vaccines and the use of genetic recombinants.

Authors:  E D Kilbourne
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

6.  Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man.

Authors:  B R Murphy; E G Chalhub; S R Nusinoff; R M Chanock
Journal:  J Infect Dis       Date:  1972-08       Impact factor: 5.226

7.  Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses.

Authors:  A S Beare; G C Schild; J W Craig
Journal:  Lancet       Date:  1975-10-18       Impact factor: 79.321

8.  Virulence for man of a human influenza-A virus antigenically similar to "classical" swine viruses.

Authors:  A S Beare; J W Craig
Journal:  Lancet       Date:  1976-07-03       Impact factor: 79.321

9.  Recombinant influenza-A viruses as live vaccines for man. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines.

Authors:  A S Beare; T S Hall
Journal:  Lancet       Date:  1971-12-11       Impact factor: 79.321

10.  Swine influenza viruses isolated in 1976 from man and pig contain two coexisting subpopulations with antigenically distinguishable hemagglutinins.

Authors:  A P Kendal; G R Noble; W R Dowdle
Journal:  Virology       Date:  1977-10-01       Impact factor: 3.616

View more
  1 in total

Review 1.  The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine.

Authors:  Sophie A Valkenburg; Nancy H L Leung; Maireid B Bull; Li-Meng Yan; Athena P Y Li; Leo L M Poon; Benjamin J Cowling
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.